tbuckley/cabot-search huggingface dataset:
Phoenix- A humanised 90Y-conjugated monoclonal antibody for the treatment of relapsed breast cancer
Authors: A. A. Epenetos, R. Ceriani, J. Peterson, P. Cagnoni, Y. Nieto, R. Jones
Journal: Journal of Clinical Oncology (2004)

632 Background: Phoenix is a 90Y-conjugated humanised IgG1 monoclonal antibody directed against a tandem repeat of deglycosylated mucin expressed in >90% of breast carcinomas. Methods: Following an imaging and pharmacokinetic study demonstrating successful targetting of approximately 80% of breast cancer lesions, a phase I-II study was conducted in 17 patients with relapsed breast cancer refractory to any available treatment. Results: Out of 17 patients treated, 8 patients had an objective response, 9 patients did not respond and 1 patient was not evaluable. Statistical analysis indicates that the difference between the responders and the non-responders for time to relapse is significant (p>0.02). Conclusions: Phoenix appears to be an active agent in relapsed breast cancer. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Somantis Limited Somantis Limited
Management of Adult Patients With Thyroid Nodules and Differentiated Thyroid Cancer
Authors: Ronald N. Cohen, Andrew M. Davis
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome
Authors: Prashant Kapoor, Shaji Kumar, Rafael Fonseca, Martha Q. Lacy, Thomas E Witzig, Suzanne R. Hayman, Angela Dispenzieri, Francis Buadi, P. Leif Bergsagel, Morie Gertz, Robert Dalton, Joseph Mikhael, David Dingli, Craig B. Reeder, John A. Lust, Stephen Russell, Vivek Roy, Steven R. Zeldenrust, Keith Stewart, Robert A Kyle, Philip R. Greipp, S. Vincent Rajkumar
Journal: Blood (2008)
A Phase II Study of Low-Dose Pomalidomide (0.5mg/day) and Prednisone Combination Therapy in Patients with Myelofibrosis and Significant Anemia
Authors: Aditi Shastri, Jorge E. Cortes, Elias J. Jabbour, Lingsha Zhou, Kurt Schroeder, Hagop M. Kantarjian, Srdan Verstovsek
Journal: Blood (2012)
Prospective Comparison on Cardiac and Hepatic Iron and Cardiac Function by MR in Thalassemia Major Patients Treated with Combination Deferiprone–Desferrioxamine Versus Deferiprone and Desferrioxamine in Monoterapy,
Authors: Alessia Pepe, Antonella Meloni, Pasquale Pepe, Marcello Capra, Domenico Giuseppe D'Ascola, Michele Santodirocco, Paolo Cianciulli, Vincenzo Caruso, Maria Antonietta Romeo, Aldo Filosa, Lorella Pitrolo, Maria Caterina Putti, Aurelio Maggio, Massimiliano Missere, Vincenzo Positano, Massimo Lombardi, Paolo Ricchi
Journal: Blood (2011)
Erratum to “Prodrugs of purine and pyrimidine analogues for the intestinal di/tri-peptide transporter PepT1: affinity for hPepT1 in Caco-2 cells, drug release in aqueous media and in vitro metabolism”
Authors: Anne Engelbrecht Thomsen, Gerda Marie Friedrichsen, Arne Hagsten Sørensen, Rikke Andersen, Carsten Uhd Nielsen, Birger Brodin, Mikael Begtrup, Sven Frokjaer, Bente Steffansen
Journal: Journal of Controlled Release (2003)
Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib
Authors: Ajai Chari, Hearn Jay Cho, Samir Parekh, Keren Osman, Talia Goldstein, Gillian Morgan, Lisa La, Crystle Carter, Donna Catamero, Juliet Escalon, Daniel Verina, Erika Florendo, Moon-hee Yum, Nadege Stevens, Jude Gullie, Elaine Chan, Sundar Jagannath
Journal: Blood (2015)
Bicarbonate reduces HT-29 cell death by preventing SN-38-induced intracellular acidification
Authors: Tadashi Ikegami, Joe Cotruvo, Yasushi Matsuzaki, Bernard E. Bouscarel
Journal: Cancer Research (2004)

2005  Background and Hypothesis: Sodium bicarbonate reduces the apoptotic effect of irinotecan (CPT-11) and its active metabolite SN-38 in cultured HT29 cells, and abrogates diarrhea in the golden Syrian hamster model receiving seven daily IP injections of CPT-11 (Cancer. Res., 62:179-187, 2002). We have proposed that one of the actions of bicarbonate was to increase the conversion of CPT-11/SN-38 lactone to its less toxic carboxylate form. The present hypothesis is that the protective action of bicarbonate is due, at least in part, to reduced CPT-11/SN-38-induced intracellular acidification. Methods: Cytotoxicity was determined by MTT assay. Intracellular pH (pHi) was determined using Snarf-1 and an ACAS 570 interactive laser cytometer. Results: SN-38 (0.5uM) lactone and carboxylate were prepared overnight at pH 6.2 and 7.6, respectively. SN-38 was added to the HT29 cell culture medium maintained either at pH 6.2 or 7.4 for 2h and the cells were washed and further incubated in fresh medium for an additional 96h. SN-38 lactone decreased cell viability by 55+1.5% whether the culture medium was maintained at pH 6.2 or 7.4, suggesting little conversion from lactone to carboxylate in the 2h incubation period. However, under the same conditions the cell toxicity induced by SN-38 carboxylate was only 33+4%, supporting a more toxic effect of the lactone than carboxylate form of SN-38. Subsequently, HT29 cells were incubated with 0.5 uM SN-38 for 2h. Cells were treated with increasing concentrations (5, 20, 44 and 100 mM) of bicarbonate either 1) before (2h), during, and after SN-38 exposure until 96h, or 2) only after SN-38 exposure up to 96h. SN38 alone induced ∼65% cell death. The cytotoxic effect of SN-38 was proportionally reduced by 0, 20, 60 and 80% with increasing concentrations of bicarbonate. The effect of bicarbonate was similar whether added before or after SN-38, suggesting that bicarbonate did not alter the cellular uptake of SN-38 and that the protective effect of bicarbonate was significant (p
High CR Rate and Prolonged EFS in aaIPI 2 – 3 Diffuse Large B-Cell Lymphoma Following High-Dose Sequential Chemotherapy and In Vivo Rituximab-Purged Stem Cell Autografting (R-HDS Regimen): Results of a Prospective Phase II Multicenter Study Sponsored by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).
Authors: Corrado Tarella, Manuela Zanni, Massimo Di Nicola, Caterina Patti, Claudia Castellino, Alessandra Pescarollo, Valerio Zoli, Daniele Caracciolo, Marco Ladetto, Michele Magni, Liliana Devizzi, Mario Boccadoro, Marco Bregni, Paolo Corradini, Andrea Gallamini, Ignazio Majolino, Salvo Mirto, Alessandro M. Gianni
Journal: Blood (2005)
HSPA5 Regulates Ferroptotic Cell Death in Cancer Cells
Authors: Shan Zhu, Qiuhong Zhang, Xiaofan Sun, Herbert J. Zeh, Michael T. Lotze, Rui Kang, Daolin Tang
Journal: Cancer Research (2017)

Abstract Ferroptosis is a form of regulated cell death driven by oxidative injury promoting lipid peroxidation, although detailed molecular regulators are largely unknown. Here, we show that heatshock 70-kDa protein 5 (HSPA5) negatively regulates ferroptosis in human pancreatic ductal adenocarcinoma (PDAC) cells. Mechanistically, activating transcription factor 4 (ATF4) resulted in the induction of HSPA5, which in turn bound glutathione peroxidase 4 (GPX4) and protected against GPX4 protein degradation and subsequent lipid peroxidation. Importantly, the HSPA5–GPX4 pathway mediated ferroptosis resistance, limiting the anticancer activity of gemcitabine. Genetic or pharmacologic inhibition of the HSPA5–GPX4 pathway enhanced gemcitabine sensitivity by disinhibiting ferroptosis in vitro and in both subcutaneous and orthotopic animal models of PDAC. Collectively, these findings identify a novel role of HSPA5 in ferroptosis and suggest a potential therapeutic strategy for overcoming gemcitabine resistance. Cancer Res; 77(8); 2064–77. ©2017 AACR.
Topical vitamin K1 in the management of skin rash during anti-EGFR monoclonal antibody treatment in patients with metastatic cancer: Italian Observational Study.
Authors: C. Pinto, C. Barone, D. Ferrari, P. Di Tullio, T. P. Latiano, A. Orlandi, F. Di Fabio, A. Cassano, F. L. Rojas Llimpe, S. Pini, A. Amoroso, E. Maiello, A. Martoni
Journal: Journal of Clinical Oncology (2011)

e14068 Background: Preclinical studies have shown that vitamin K1 reactivated EGFR-mediated signal transduction after inhibition via EGFR receptor antagonists. The aim of this study was to evaluate the impact of vitamin K1 cream in skin rash management. Methods: In four Italian oncology centers sequential pts at the first therapy with cetuximab/panitumumab for metastatic cancer were treated with vitamin K1 cream before the start of treatment (group A) or at the earliest onset of grade ≥2 skin rash (group B). Topical treatment with vitamin K1 (Phytomenadione 0.1%) cream twice/day was performed both in group A and B continuously until the end of cetuximab/panitumumab treatment. Skin toxicity, according to NCI-CTC v3.0 grading system, was clinically evaluated every two weeks and in a standardized way, by taking pictures of 5 different body areas (face, fore/back-thorax, foot, right hand). Results: From February to December 2010, 51 pts (16 group A and 35 group B), 35M (68.6%) and 16F (31.4%), median age 63 years (range 28-82), were evaluated. The primary tumor site was 3 (5.9%) esophagus/stomach, 41 (80.4%) colon-rectum, 7 (13.7%) head-neck. Thirty-two (62.7%) pts were treated as first-line and 19 (37.3%) were pretreated. The regimen contained cetuximab in 41 (80.4%) pts and panitumumab in 10 (19.6%). The combination regimens were platinum-compounds-based in 27 (52.9%) pts, and irinotecan-based in 17 (33.4%); panitumumab was administered in monotherapy in 7 (13.7%) pts. The median time of vitamin K1 cream treatment in group A and B was 9 weeks (range 2-42) and 12 weeks (range 4-43) respectively. In group A all grade skin rash was observed in 14 (87.5%) pts and grade 2 in 2 (12.5%) pts; no grade >2 was detected. In group B the skin rash decrease to grade 0-1 was observed in 13 (37.1%) pts, and 13 (37.1%) pts showed unchanged grade 2; the increase to grade 3 skin rash was observed in just 9 (25.7%) pts. At least one modification in cetuximab/panitumumab treatment was required in 1 (6.3%) pts of group A and 9 (25.7%) of group B. Conclusions: These results suggest a favorable impact of vitamin K1 cream in skin rash management, which should be considered in a future clinical trial.
Has increased provision of treatment reduced the prevalence of common mental disorders? Review of the evidence from four countries
Authors: Anthony F. Jorm, Scott B. Patten, Traolach S. Brugha, Ramin Mojtabai
Journal: World Psychiatry (2017)

Many people identified as having common mental disorders in community surveys do not receive treatment. Modelling has suggested that closing this “treatment gap” should reduce the population prevalence of those disorders. To evaluate the effects of reducing the treatment gap in industrialized countries, data from 1990 to 2015 were reviewed from four English‐speaking countries: Australia, Canada, England and the US. These data show that the prevalence of mood and anxiety disorders and symptoms has not decreased, despite substantial increases in the provision of treatment, particularly antidepressants. Several hypotheses for this lack of improvement were considered. There was no support for the hypothesis that reductions in prevalence due to treatment have been masked by increases in risk factors. However, there was little evidence relevant to the hypothesis that improvements have been masked by increased reporting of symptoms because of greater public awareness of common mental disorders or willingness to disclose. A more strongly supported hypothesis for the lack of improvement is that much of the treatment provided does not meet the minimal standards of clinical practice guidelines and is not targeted optimally to those in greatest need. Lack of attention to prevention of common mental disorders may also be a factor. Reducing the prevalence of common mental disorders remains an unsolved challenge for health systems globally, which may require greater attention to the “quality gap” and “prevention gap”. There is also a need for nations to monitor outcomes by using standardized measures of service provision and mental disorders over time.
A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis
Authors: Julien Bissonnette, José Altamirano, Cécile Devue, Olivier Roux, Audrey Payancé, Didier Lebrec, Pierre Bedossa, Dominique Valla, François Durand, Hafid Ait‐Oufella, Pau Sancho‐Bru, Joan Caballeria, Pere Ginès, Chantal M. Boulanger, Ramon Bataller, Pierre‐Emmanuel Rautou
Journal: Hepatology (2017)

The diagnosis of alcoholic hepatitis (AH) often requires a transjugular liver biopsy (TJLB), a procedure that is not always readily accessible. We analyzed plasma biomarkers to estimate the presence of histological features of AH among patients with clinical suspicion of AH. Using enzyme‐linked immunosorbent assay, we tested M65 and M30 (circulating fragments of cytokeratin‐18) and their respective fraction carried by microvesicles (MVs), CCL20 and TREM1. Leukocyte, platelet, and endothelial‐derived MVs were quantified by way of flow cytometry. Test and validation cohorts prospectively included patients with clinical features of AH undergoing TJLB. In the test cohort, 46 of 83 (55%) patients showed histological features of AH. Age, bilirubin, INR, and creatinine (ABIC) score was B or C in 83%. Patients with histologically proven AH had higher levels of total and MV‐bound M65 and total and MV‐bound M30 and CCL20 than those without ( P &lt; 0.001 for all tests). Levels of TREM‐1 and of subpopulations of MVs were not different between groups. M65 and M30 both had an area under the receiver operating characteristics curve of 0.84 to estimate the presence of AH. For M65, a cutoff of 2000 IU/L had a positive predictive value of 91%, whereas a cutoff of 641 IU/L had a negative predictive value of 88%. In the validation cohort, AH was histologically confirmed in 48 of 68 (71%) patients. ABIC score was B or C in 69% of patients. For M65, the above cutoffs had a diagnostic accuracy of 81%. Even better results were obtained in patients with suspicion of severe AH (ABIC B or C) in both cohorts. Conclusion : Plasma levels of cytokeratin‐18 fragments are reliable noninvasive markers of AH. Using the proposed cutoffs for M65, two thirds of TJLB can be avoided, which can be useful in centers where this technique is not readily available. (H epatology 2017;66:555–563).
RETRACTED ARTICLE: Quercetin-induced miR-200b-3p regulates the mode of self-renewing divisions in pancreatic cancer
Authors: Clifford C. Nwaeburu, Alia Abukiwan, Zhefu Zhao, Ingrid Herr
Journal: Molecular Cancer (2017)

Cancer stem cells are suggested to contribute to the extremely poor prognosis of pancreatic ductal adenocarcinoma and dysregulation of symmetric and asymmetric stem cell division may be involved. Anticancer benefits of phytochemicals like the polyphenol quercetin, present in many fruits, nuts and vegetables, could be expedited by microRNAs, which orchestrate cell-fate decisions and tissue homeostasis. The mechanisms regulating the division mode of cancer stem cells in relation to phytochemical-induced microRNAs are poorly understood.Patient-derived pancreas tissue and 3 established pancreatic cancer cell lines were examined by immunofluorescence and time-lapse microscopy, microRNA microarray analysis, bioinformatics and computational analysis, qRT-PCR, Western blot analysis, self-renewal and differentiation assays.We show that symmetric and asymmetric division occurred in patient tissues and in vitro, whereas symmetric divisions were more extensive. By microarray analysis, bioinformatics prediction and qRT-PCR, we identified and validated quercetin-induced microRNAs involved in Notch signaling/cell-fate determination. Further computational analysis distinguished miR-200b-3p as strong candidate for cell-fate determinant. Mechanistically, miR-200b-3p switched symmetric to asymmetric cell division by reversing the Notch/Numb ratio, inhibition of the self-renewal and activation of the potential to differentiate to adipocytes, osteocytes and chondrocytes. Low miR-200b-3p levels fostered Notch signaling and promoted daughter cells to become symmetric while high miR-200b-3p levels lessened Notch signaling and promoted daughter cells to become asymmetric.Our findings provide a better understanding of the cross talk between phytochemicals, microRNAs and Notch signaling in the regulation of self-renewing cancer stem cell divisions.
Connective Tissue Growth Factor Domain 4 Amplifies Fibrotic Kidney Disease through Activation of LDL Receptor–Related Protein 6
Authors: Bryce G. Johnson, Shuyu Ren, Gamze Karaca, Ivan G. Gomez, Cécile Fligny, Benjamin Smith, Ayla Ergun, George Locke, Benbo Gao, Sebastian Hayes, Scott MacDonnell, Jeremy S. Duffield
Journal: Journal of the American Society of Nephrology (2017)

Connective tissue growth factor (CTGF), a matrix-associated protein with four distinct cytokine binding domains, has roles in vasculogenesis, wound healing responses, and fibrogenesis and is upregulated in fibroblasts and myofibroblasts in disease. Here, we investigated the role of CTGF in fibrogenic cells. In mice, tissue-specific inducible overexpression of CTGF by kidney pericytes and fibroblasts had no bearing on nephrogenesis or kidney homeostasis but exacerbated inflammation and fibrosis after ureteral obstruction. These effects required the WNT receptor LDL receptor–related protein 6 (LRP6). Additionally, pericytes isolated from these mice became hypermigratory and hyperproliferative on overexpression of CTGF. CTGF is cleaved in vivo into distinct domains. Treatment with recombinant domain 1, 1+2 (N terminus), or 4 (C terminus) independently activated myofibroblast differentiation and wound healing responses in cultured pericytes, but domain 4 showed the broadest profibrotic activity. Domain 4 exhibited low-affinity binding to LRP6 in in vitro binding assays, and inhibition of LRP6 or critical signaling cascades downstream of LRP6, including JNK and WNT/ β -catenin, inhibited the biologic activity of domain 4. Administration of blocking antibodies specifically against CTGF domain 4 or recombinant Dickkopf–related protein-1, an endogenous inhibitor of LRP6, effectively inhibited inflammation and fibrosis associated with ureteral obstruction in vivo . Therefore, domain 4 of CTGF and the WNT signaling pathway are important new targets in fibrosis.
Expression of LMO3 and SNAP25 in Diffuse Large B-Cell Lymphoma Cells and Its Relation to Clinical Features
Authors: Kyoko Kobayashi, Motoko Yamaguchi, Kana Miyazaki, Hiroshi Imai, Kaori Yokoe, Ryoichi Ono, Tetsuya Nosaka, Naoyuki Katayama
Journal: Blood (2014)
Clinicopathological Features of Pyothorax-Associated Lymphoma; a Retrospective Survey Involving 98 Patients.
Authors: Hiroto Narimatsu, Yasunori Ota, Masahiro Kami, Kengo Takeuchi, Ritsuro Suzuki, Keitaro Matsuo, Yukiko Kishi, Tamae Hamaki, Yuji Tanaka, Shigeo Nakamura
Journal: Blood (2006)
Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era: A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource
Authors: Brian K Link, Matthew J Maurer, Grzegorz S. Nowakowski, Stephen M Ansell, William R Macon, Sergei I Syrbu, Susan L Slager, Carrie A. Thompson, David J. Inwards, Patrick B. Johnston, Joseph P. Colgan, Thomas E. Witzig, George J Weiner, Thomas M. Habermann, James R Cerhan
Journal: Blood (2012)
A Non-Radiation-Containing, Intermediate-Dose Methotrexate (MTX) Regimen Resulted in Favorable Survival without Progression of Dementia in Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL).
Authors: Kenich Taoka, Yasushi Okoshi, Yuichi Hasegawa, Shigeru Chiba
Journal: Blood (2009)
A Comparison of Two Different Reduced Intensity Conditioning (RIC) Allograft Strategies In Patients with Multiple Myeloma, An EBMT Analysis
Authors: Firoozeh Sahebi, Laurent Garderet, Simona Iacobelli, Anja van Biezen, Gösta Gahrton, Nicolaus Kröger, Theo de Witte, Curly Morris
Journal: Blood (2010)
Development of Non-Anticoagulant Derivatives of Biotechnology Derived Sulfaminoheparosan Derivatives to Investigate the Non-Anticoagulant Effects of these Agents.
Authors: Umberto Cornelli, Jyothi Maddineni, Laurel Vana, Debra Hoppensteadt, Michelle Florian-Kujawski, Jawed Fareed
Journal: Blood (2004)
Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901).
Authors: Vicki A. Morrison, Bercedis L. Peterson, Kanti R. Rai, John C. Byrd, Richard A. Larson
Journal: Blood (2007)
Still Another Case of Right Lower Quadrant Abdominal Pain
Authors: Francesco Maria Carrano, Socrate Mauri, Pio Francesco Interdonato
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal